<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Inovio Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc</link>
<description>Latest news and press releases for Inovio Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/inovio-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583f778dffbe2df0fce90.webp</url>
<title>Inovio Pharmaceuticals Inc</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc</link>
</image>
<item>
<title>INOVIO Announces Pricing of $17.5 Million Public Offering</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-announces-pricing-of-dollar175-million-public-offering-38</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-announces-pricing-of-dollar175-million-public-offering-38</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa., April 2, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and</description>
</item>
<item>
<title>INOVIO to Participate in Upcoming Scientific Conference</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-to-participate-in-upcoming-scientific-conference-5</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-to-participate-in-upcoming-scientific-conference-5</guid>
<pubDate>Wed, 01 Apr 2026 12:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conference:</description>
</item>
<item>
<title>INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2025 and provided an update on recent company developments.</description>
</item>
<item>
<title>INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026-70</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-to-report-fourth-quarter-and-full-year-2025-financial-results-on-march-12-2026-70</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to</description>
</item>
<item>
<title>Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/akeso-and-inovio-announce-clinical-collaboration-to-advance-novel-combination-therapy-for-glioblastoma-gbm-49</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/akeso-and-inovio-announce-clinical-collaboration-to-advance-novel-combination-therapy-for-glioblastoma-gbm-49</guid>
<pubDate>Wed, 04 Mar 2026 13:52:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso"), and INOVIO (NASDAQ: INO) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with INO-5412, INOVIO's DNA immunotherapy candidate, for the potential treatment of GBM. The combination therapy will be studied as a part of INSIGhT, the innovative Phase II adaptive platform trial sponsored by the Dana-Farber Cancer Institute and c</description>
</item>
<item>
<title>INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-and-akeso-announce-clinical-collaboration-to-advance-novel-combination-therapy-for-glioblastoma-gbm</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-and-akeso-announce-clinical-collaboration-to-advance-novel-combination-therapy-for-glioblastoma-gbm</guid>
<pubDate>Wed, 04 Mar 2026 13:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), and Akeso, Inc. (9926.HK) ("Akeso") today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO's DNA immunotherapy candidate, in combination with cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, for the potential treatment of GBM. The combination therapy will be studied as a part of INSIGhT, the innovative Phase 2 adaptive platform trial sponsored by the Dana-Farber Cancer Institute and co</description>
</item>
<item>
<title>INOVIO to Participate in Upcoming Scientific and Investor Conferences</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-participate-upcoming-scientific-investor-130500090</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-participate-upcoming-scientific-investor-130500090</guid>
<pubDate>Thu, 12 Feb 2026 13:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific and investor conferences:</description>
</item>
<item>
<title>FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/fda-accepts-review-inovios-bla-130500666</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/fda-accepts-review-inovios-bla-130500666</guid>
<pubDate>Mon, 29 Dec 2025 13:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for INO-3107 for review as a potential treatment for adults with RRP. The review classification designated by FDA is Standard.</description>
</item>
<item>
<title>INOVIO Reports Inducement Grant Under Inducement Plan</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-reports-inducement-grant-under-210500917</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-reports-inducement-grant-under-210500917</guid>
<pubDate>Fri, 19 Dec 2025 21:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").</description>
</item>
<item>
<title>INOVIO to Participate in December Investor Conferences</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-participate-december-investor-conferences-130500261</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-participate-december-investor-conferences-130500261</guid>
<pubDate>Tue, 18 Nov 2025 13:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences:</description>
</item>
<item>
<title>INOVIO Announces Pricing of $25 Million Public Offering</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-announces-pricing-25-million-134000239</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-announces-pricing-25-million-134000239</guid>
<pubDate>Tue, 11 Nov 2025 13:40:00 GMT</pubDate>
<description>INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 13,158,000 shares of its common stock at a public offering price of $1.90 per share. All of the shares of common stock in the offering are being sold by INOVIO. The offering is expected to close on or about November 1</description>
</item>
<item>
<title>INOVIO Announces Proposed Public Offering</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-announces-proposed-public-offering-230900941</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-announces-proposed-public-offering-230900941</guid>
<pubDate>Mon, 10 Nov 2025 23:09:00 GMT</pubDate>
<description>INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the proposed offering will be sold by INOVIO. INOVIO intends to grant the underwriter a 30-day option to purchase additional shares o</description>
</item>
<item>
<title>INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-reports-third-quarter-2025-210500042</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-reports-third-quarter-2025-210500042</guid>
<pubDate>Mon, 10 Nov 2025 21:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2025 and provided an update on recent company developments.</description>
</item>
<item>
<title>INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-completes-rolling-bla-submission-130500745</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-completes-rolling-bla-submission-130500745</guid>
<pubDate>Mon, 03 Nov 2025 13:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has completed the rolling submission of its Biologics License Application (BLA) for its DNA immunotherapy candidate INO-3107 for the treatment of RRP in adults.</description>
</item>
<item>
<title>INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-report-third-quarter-2025-120500754</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-report-third-quarter-2025-120500754</guid>
<pubDate>Mon, 27 Oct 2025 12:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its third quarter 2025 financial results will be released after the market close on November 10, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update.</description>
</item>
<item>
<title>INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-participate-stephens-biotechnology-virtual-200500311</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-participate-stephens-biotechnology-virtual-200500311</guid>
<pubDate>Thu, 23 Oct 2025 20:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat at the upcoming Stephens Biotechnology Virtual Fireside Chat Conference. During the conference, members of INOVIO's management team will also be conducting one-on-one meetings with investors.</description>
</item>
<item>
<title>Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/clinical-proof-concept-data-dna-120500743</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/clinical-proof-concept-data-dna-120500743</guid>
<pubDate>Tue, 21 Oct 2025 12:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced results from a Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19 were published online in Nature Medicine under the title "Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial." Interim pharmacokinetic results were previ</description>
</item>
<item>
<title>INOVIO to Participate in Upcoming Scientific Conferences</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-participate-upcoming-scientific-conferences-120500729</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-participate-upcoming-scientific-conferences-120500729</guid>
<pubDate>Thu, 25 Sep 2025 12:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present data at a number of upcoming scientific conferences, highlighting key aspects of lead product candidate INO-3107 for RRP. INOVIO has begun the rolling submission of its Biologics License Application (BLA) for INO-3107, which it anticipates completing in the second hal</description>
</item>
<item>
<title>INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-begin-rolling-submission-bla-120500663</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-begin-rolling-submission-bla-120500663</guid>
<pubDate>Tue, 26 Aug 2025 12:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the FDA has notified INOVIO that it agrees with its rolling submission timeline for the BLA for INO-3107 as a treatment for adults with Recurrent Respiratory Papillomatosis (RRP.) INOVIO anticipates completing its submission to the FDA in the coming months and requesting priority rev</description>
</item>
<item>
<title>INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-participate-h-c-wainwright-120500201</link>
<guid isPermaLink="true">https://6ix.com/company/inovio-pharmaceuticals-inc/news/inovio-participate-h-c-wainwright-120500201</guid>
<pubDate>Mon, 25 Aug 2025 12:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that a pre-recorded presentation from the Company will be available on demand as a part of the H.C. Wainwright 27th Annual Global Investment Conference in New York. During the conference, members of INOVIO's management team will also be conducting in-person one-on-one meetings with inves</description>
</item>
</channel>
</rss>